Press Releases

Read about the latest Hoth Therapeutics
technology, research, investor updates
and much more.

Oct 19, 2021

Hoth Therapeutics Extends Partnership Agreement with REPROCELL

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh...

Oct 12, 2021

Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence cohort 2 of the Phase 1b...

Sep 21, 2021

Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that a Safety Review Committee (SRC) has reviewed the safety data from the first cohort of...

View All

Our Purpose

Founded in 2017, Hoth Therapeutics, Inc. was formed as a global platform to commercialize innovative and proprietary therapeutics. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders.

Home Page Icons